Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090932 | 0.92 | CA2 (0.42) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3100767 | 0.90 | CA2 (0.41) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL976399 | 0.90 | ALDH1A1 (0.54) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL236337 | 0.89 | ALDH1A1 (0.35) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3097258 | 0.87 | CA2 (0.47) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL1442563 | 0.86 | — | — | |
| SCHEMBL3093790 | 0.85 | LMNA (0.50) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL497448 | 0.83 | — | — | |
| SCHEMBL382576 | 0.80 | ALDH1A1 (0.62) | CA2ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL23498284 | 0.80 | ALDH1A1 (0.50) | CA2ALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223888-A1 | METHOD FOR PRODUCING POLYCARBONATE RESIN, AND ALICYCLIC POLYCARBONATE RESIN | 旭化成株式会社 | 2023-11-23 | — | — | WO | disclosed |
| US-20230159727-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2023-05-25 | — | — | US | disclosed |
| EP-3935052-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2022-01-12 | — | — | EP | disclosed |
| CN-113544126-A | Hindered amine stabilizer mixtures | 巴斯夫欧洲公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-109721723-B | Surfactant, method for producing the same, and solution containing the same | 中日合成化学股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| WO-2020182587-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | BASF SE (DE) | 2020-09-17 | — | — | WO | disclosed |
| US-9944623-B2 | Sterically hindered amine stabilizer | BASF SE (DE) | 2018-04-17 | — | — | US | disclosed |
| EP-2475655-B1 | STERICALLY HINDERED AMINE STABILIZER | BASF SE (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20160347736-A1 | STERICALLY HINDERED AMINE STABILIZER | BASF SE (DE) | 2016-12-01 | — | — | US | disclosed |
| US-9464070-B2 | Sterically hindered amine stabilizer | BASF SE (DE) | 2016-10-11 | — | — | US | disclosed |
| US-5650430-A | Radicicol derivatives, their preparation and their anti-tumor activity | SANKYO COMPANY, LIMITED (JP) | 1997-07-22 | — | — | US | disclosed |
| EP-0460950-B1 | Radicicol derivatives, their preparation and their anti-tumour activity | SANKYO CO (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5597846-A | ESTERS OF RADICICOL | SANKYO COMPANY, LIMITED (JP) | 1997-01-28 | — | — | US | disclosed |
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347736-A1 | STERICALLY HINDERED AMINE STABILIZER | H1-10, H1-0, H1-3 | CA2 4331/4885ALDH1A1 217/4885TDP1 3152/4885 |
| US-20230159727-A1 | STERICALLY HINDERED AMINE STABILIZER MIXTURES | PYM1, H1-4, C5 | CA2 2784/4885ALDH1A1 1799/4885TDP1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.